SUSAN ABUGHOSH to Aged
This is a "connection" page, showing publications SUSAN ABUGHOSH has written about Aged.
Connection Strength
1.765
-
Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data. Cancer Treat Res Commun. 2025; 43:100921.
Score: 0.068
-
Group-based trajectory modeling to identify longitudinal patterns and predictors of adherence among older adults on concomitant triple therapy (oral antidiabetic, renin-angiotensin-system antagonists, statins). J Manag Care Spec Pharm. 2025 Apr; 31(4):396-405.
Score: 0.068
-
Marginal structural models to evaluate the association between adherence to direct oral anticoagulants and safety or efficacy outcomes among patients with atrial fibrillation. J Am Pharm Assoc (2003). 2025 May-Jun; 65(3):102355.
Score: 0.068
-
Real-world treatment patterns in drug na?ve type 2 diabetes population: Initial combination therapy vs. sequential step-therapy. J Am Pharm Assoc (2003). 2025 Jan-Feb; 65(1):102295.
Score: 0.067
-
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
Score: 0.066
-
Group-based trajectory modeling to identify adherence patterns for direct oral anticoagulants in Medicare beneficiaries with atrial fibrillation: a real-world study on medication adherence. Int J Clin Pharm. 2024 Dec; 46(6):1525-1535.
Score: 0.066
-
Predictors of adherence to direct oral anticoagulants after cardiovascular or bleeding events in Medicare Advantage Plan enrollees with atrial fibrillation. J Manag Care Spec Pharm. 2024 May; 30(5):408-419.
Score: 0.064
-
Trajectories of adherence to ACEI/ARB medications following a motivational interviewing intervention among Medicare Advantage beneficiaries in Texas. Patient Educ Couns. 2024 Feb; 119:108073.
Score: 0.062
-
A Motivational Interviewing Intervention to Improve Adherence to ACEIs/ARBs among Nonadherent Older Adults with Comorbid Hypertension and Diabetes. Drugs Aging. 2023 04; 40(4):377-390.
Score: 0.059
-
Evaluating Adherence to Concomitant Diabetes, Hypertension, and Hyperlipidemia Treatments and Cardiovascular Outcomes Among Elderly Patients Using Marginal Structural Modeling. High Blood Press Cardiovasc Prev. 2022 Nov; 29(6):601-610.
Score: 0.057
-
Group based trajectory modeling to assess adherence to oral anticoagulants among atrial fibrillation patients with comorbidities: a retrospective study. Int J Clin Pharm. 2022 Aug; 44(4):966-974.
Score: 0.057
-
Evaluating adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments and intermediate outcomes among elderly patients using marginal structural modeling. Pharmacotherapy. 2022 07; 42(7):518-528.
Score: 0.056
-
Adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments among older patients. J Am Pharm Assoc (2003). 2022 Jul-Aug; 62(4):1351-1358.
Score: 0.055
-
Identifying adherent patients to newly initiated statins using previous adherence to chronic medications. J Manag Care Spec Pharm. 2021 Feb; 27(2):186-197.
Score: 0.051
-
Impact of a motivational interviewing intervention targeting statins on adherence to concurrent hypertension or diabetes medications. Patient Educ Couns. 2021 07; 104(7):1756-1764.
Score: 0.051
-
Risk of Cardiovascular Outcomes and Antihypertensive Triple Combination Therapy Among Elderly Patients with Hypertension Enrolled in a Medicare Advantage Plan (MAP). Am J Cardiovasc Drugs. 2020 Dec; 20(6):591-602.
Score: 0.051
-
Patient-reported barriers to statin adherence: Excerpts from a?motivational interviewing intervention in older adults. J Am Pharm Assoc (2003). 2021 Jan-Feb; 61(1):60-67.e1.
Score: 0.050
-
Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug; 21(4):829-836.
Score: 0.050
-
Evaluating trajectories of statin adherence after a motivational interviewing intervention. J Am Pharm Assoc (2003). 2020 Nov - Dec; 60(6):892-898.
Score: 0.049
-
Evaluating Success Factors of a Medication Adherence Tracker Pilot Program in Improving Part D Medication Adherence Metrics in a Medicare Advantage Plan: Importance of Provider Engagement. J Manag Care Spec Pharm. 2020 May; 26(5):662-667.
Score: 0.049
-
A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy. Medicine (Baltimore). 2020 Apr; 99(16):e19603.
Score: 0.048
-
Enhancing Statin Adherence Using a Motivational Interviewing Intervention and Past Adherence Trajectories in Patients with Suboptimal Adherence. J Manag Care Spec Pharm. 2019 Oct; 25(10):1053-1062.
Score: 0.047
-
Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan. J Manag Care Spec Pharm. 2019 Jun; 25(6):678-686.
Score: 0.046
-
Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2019 Apr; 174(2):297-305.
Score: 0.044
-
A Motivational Interviewing Intervention by Pharmacy Students to Improve Medication Adherence. J Manag Care Spec Pharm. 2017 May; 23(5):549-560.
Score: 0.040
-
A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan. J Manag Care Spec Pharm. 2016 Jan; 22(1):63-73.
Score: 0.036
-
Comparison of Diabetes Risk Following Smoking Cessation Treatment Using Varenicline Versus Bupropion Among Obese Smokers. Subst Use Misuse. 2015; 50(13):1628-37.
Score: 0.036
-
The relationship between obesity and prescription of smoking cessation medications. Popul Health Manag. 2014 Jun; 17(3):172-9.
Score: 0.032
-
Predictors of smoking cessation medication use among nonobese and obese smokers. Subst Use Misuse. 2014 May; 49(6):752-61.
Score: 0.032
-
Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. Pharmacotherapy. 2005 Dec; 25(12):1729-35.
Score: 0.018
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
Score: 0.017
-
Racial and Ethnic Disparities in Access to Care Among Adults with Cardiovascular Disease. J Health Care Poor Underserved. 2025; 36(1):96-114.
Score: 0.017
-
Racial and Ethnic Disparities in Perceived Health Status Among Patients With Cardiovascular Disease. Prev Chronic Dis. 2024 Nov 14; 21:E89.
Score: 0.017
-
Delirium event and associated treatment modifications among older adults with Alzheimer's disease: An interrupted time-series analysis of Medicare data. Pharmacotherapy. 2024 Oct; 44(10):782-793.
Score: 0.016
-
Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manag Care Pharm. 2004 Sep-Oct; 10(5):404-11.
Score: 0.016
-
Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study. Support Care Cancer. 2024 Jun 04; 32(7):407.
Score: 0.016
-
Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer's Disease Initiating Cholinesterase Inhibitors. Drugs Aging. 2024 Apr; 41(4):339-355.
Score: 0.016
-
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer. 2023 04 01; 129(7):1051-1063.
Score: 0.015
-
Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb; 198(1):159-166.
Score: 0.015
-
Patterns of Lipid Lowering Therapy Use Among Older Adults in a Managed Care Advantage Plan in the United States. J Pharm Pract. 2024 Feb; 37(1):123-131.
Score: 0.014
-
Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes. Breast Cancer Res Treat. 2022 Oct; 195(3):421-430.
Score: 0.014
-
Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Clin Breast Cancer. 2020 12; 20(6):520-526.
Score: 0.012
-
Effect of coverage gap on healthcare utilization among Medicare beneficiaries with chronic obstructive pulmonary disorder. Curr Med Res Opin. 2019 02; 35(2):321-328.
Score: 0.011
-
Evaluating Pharmacist-Written Recommendations to Providers in a Medicare Advantage Plan: Factors Associated with Provider Acceptance. J Manag Care Spec Pharm. 2016 Jan; 22(1):49-55.
Score: 0.009
-
The Role of Socioeconomic Status and Health Care Access in Breast Cancer Screening Compliance Among Hispanics. J Public Health Manag Pract. 2015 Sep-Oct; 21(5):467-76.
Score: 0.009
-
CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer: Findings from a SEER-Medicare-based population study. Am J Clin Oncol. 2015 Apr; 38(2):165-73.
Score: 0.009